Furthermore, regarding up‐regulation of CD86, dSLIM® leads to a fourfold better activation of monocytes including secretion of immunomodulatory cytokines (IP‐10) and processing of tumor‐associated antigens 43, 44; compared to ProMune®, dSLIM® leads to almost fourfold better activation of NK cells as well as a twofold better activation of NKT cells, both representing effector cells directly attacking tumor cells 45. Here, CD86 is linked to neoplasm.